LIFESENSORS, INC.
Tau-targeting PROTAC molecules for degradation of pathological tau protein aggregates in neurodegenerative diseases
- Sector
- Biotech
- Headquarters
- Malvern, PA
- Total capital
- $11.2M
- Federal grants
- $11.2M
- 17 awards · 2015–2024
- Rank in peer group#43 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $24K
- 1 award · Health and Human S
- Rank in Biotech#369 of 4373
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Molecular glue degraders for LRRK2$300K
- Federal grantHealth and Human S · Phase II · Novel Approaches for Tau PROTAC Drug Discovery$1.2M
- Federal grantHealth and Human S · Phase II · Novel Approaches for Tau PROTAC Drug Discovery$1.3M
- Federal grantHealth and Human S · Phase II · Rational design of bifunctional protein degrader drugs$734K
- Federal grantHealth and Human S · Phase II · Rational design of bifunctional protein degrader drugs$1.7M
- Federal grantHealth and Human S · Phase I · Novel Approaches for PROTAC Drug Discovery$397K
- Federal grantHealth and Human S · Phase II · Ubiquitin Proteasome System and Molecular Signatures of Alzheimer's Disease$785K
Show 11 earlier federal awards
- Federal grantHealth and Human S · Phase I · Development of Non-conventional PROTACs$300K
- Federal grantHealth and Human S · Phase II · Ubiquitin Proteasome System and Molecular Signatures of Alzheimer’s Disease$1M
- Federal grantHealth and Human S · Phase I · Rational design of bifunctional protein degrader drugs$300K
- Federal grantHealth and Human S · Phase I · Determining the signatures of pan-ubiquitylation in the immune proteome as highly sensitive and effective markers for neurodegenerative disease$225K
- Federal grantHealth and Human S · Phase II · Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease$780K
- Federal grantHealth and Human S · Phase II · Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease$719K
- Federal grantHealth and Human S · Phase I · Development of chain selective polyubiquitin markers as early detectors of Parkinson’s and Alzheimer’s Disease$190K
- Federal grantHealth and Human S · Phase I · Novel assays for assessing protein-protein interactions in Alzheimer's disease$225K
- Federal grantHealth and Human S · Phase I · Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease$225K
- Federal contractHealth and Human S · UB-CHOP2 Detection Reagent Kits$24K
- Federal grantHealth and Human S · Phase II · Development of linkage-specific ubiquitin binding elements$739K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#43 · top 8%
- Linked publications#37 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 5- PendingMethods And Compositions For Enhanced Protein Expression And PurificationUSPTOApplication PCTUS2007089035
- PendingCompositions, Methods, And Kits For Enhancing Protein Expression, Solubility And IsolationUSPTOApplication PCTUS2005047210
- PendingMethods And Compositions For Enhanced Protein Expression And PurificationUSPTOApplication PCTUS2004020778
Show all 5 patent records
- Methods And Compositions For Enhanced Protein Expression And PurificationApplication PCTUS2007089035Pending
- Compositions, Methods, And Kits For Enhancing Protein Expression, Solubility And IsolationApplication PCTUS2005047210Pending
- Methods And Compositions For Enhanced Protein Expression And PurificationApplication PCTUS2004020778Pending
- Methods And Compositions For Protein Expression And PurificationApplication PCTUS2003000436Pending
- Compositions And Methods For Gender SortingApplication PCTUS2002012590Pending
Recent research by its founders
- The role of phospho-ubiquitin in mitochondrial health and diseases20261 cites
- Phospho-ubiquitin: rewriting the ubiquitin code20260 cites
- Unraveling chain specific ubiquitination in cells using tandem ubiquitin binding entities20254 cites
Related companies, and why
- Precision Biologics, Inc.Similar federal contract value in Biotech · $26K in contracts
- SPECTRAGEN INFORMATICS, LLCSimilar federal contract value in Biotech · $25K in contracts
- ARC Medical Inc.Similar federal contract value in Biotech · $24K in contracts
- Harvard Apparatus Regenerative Technology, Inc.Similar federal contract value in Biotech · $22K in contracts
- TriSalus Life Sciences, Inc.Similar federal contract value in Biotech · $22K in contracts
- Circulomics Inc.Similar federal contract value in Biotech · $19K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .